Search Results for "Celltrion Remsima"
Original Source: Biosimilar drugs' cost-savings still out of reach
The prospect of reducing health care costs through use of biosimilar drugs has has hit roadblocks in the form of setbacks for -More-
Matching Channels
None
Matching News
On Heels of Remsima Launch, Celltrion Gears Up For Herceptin Biosimilar Approval In Korea
Following the start of sales of Remsima, a biosimilar of J&J’s Remicade, Celltrion is moving to begin selling its Herceptin biosimilar in Korea this year. It will be Celltron’s second biosimil...
Korea’s Celltrion Expects Price Of Remsima Biosimilar To Be 70% Of Remicade
Celltrion expects Korea’s National Health Insurance to cover Remsima and to start sales in the third quarter.
Celltrion amends timeline for rituximab biosimilar
Celltrion Inc. (KOSDAQ:068270) said it plans to start a Phase III trial of CT-P10, its biosimilar rituximab, in 2H13. Celltrion had planned to conduct Phase I and Phase III testing simultaneously, but...
World's first biosimilar MAb approved: infliximab in South Korea
South Korea has granted the first approval worldwide to a biosimilar version of Johnson & Johnson/ Merck & Co's blockbuster biologic Remicade (infliximab). The regulatory clearance of Celltrion's Rem...
Biosimilar monoclonal antibody approved in Korea
South Korean biotechnology company Celltrion announced on 23 July 2012 that the Korean Food and Drug Administration (KFDA) had approved its first monoclonal antibody, Remsima.
Celltrion CEO Cites Pfizer, J&J and Sanofi As Potential Buyers For Biosimilars Business
Although Korea’s Celltrion is not in takeover talks yet, CEO Seo Jung-jin named potential buyers after announcing he would sell his stake in the company he founded. Celltrion is expecting approval s...
Celltrion CEO Cites Pfizer, J&J and Sanofi As Potential Buyers For Biosimilars Business
Although Korea’s Celltrion is not in takeover talks yet, CEO Seo Jung-jin named potential buyers after announcing he would sell his stake in the company he founded. Celltrion is expecting approval s...
First approval for biosimilar infliximab, in South Korea (update)
South Korea has granted the first approval worldwide to a biosimilar version of Johnson & Johnson/ Merck & Co's blockbuster biologic therapy Remicade (infliximab). The regulatory clearance of Celltri...
Matching PubMed Articles
None
